Ekso Bionics - EKSO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.25
  • Forecasted Upside: 622.66%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.28
▲ +0.1 (8.47%)

This chart shows the closing price for EKSO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ekso Bionics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EKSO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EKSO

Analyst Price Target is $9.25
▲ +622.66% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Ekso Bionics in the last 3 months. The average price target is $9.25, with a high forecast of $9.25 and a low forecast of $9.25. The average price target represents a 622.66% upside from the last price of $1.28.

This chart shows the closing price for EKSO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Ekso Bionics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/5/2024HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $9.25Low
1/22/2024HC WainwrightBoost TargetBuy ➝ Buy$9.00 ➝ $10.00Low
4/28/2023500.comReiterated RatingReiteratesLow
3/30/2023HC WainwrightReiterated RatingBuy$9.00Low
7/29/2022HC WainwrightLower TargetBuy$11.00 ➝ $9.00Low
11/3/2021HC WainwrightReiterated RatingBuyMedium
7/30/2021HC WainwrightReiterated RatingBuy$11.00Medium
2/15/2021AegisReiterated RatingBuyHigh
10/30/2020HC WainwrightLower TargetBuy$12.00 ➝ $11.00High
8/3/2020AegisLower TargetBuy$13.00 ➝ $9.00Low
7/31/2020HC WainwrightReiterated RatingBuy$12.00High
6/26/2020HC WainwrightReiterated RatingBuy$8.00 ➝ $12.00High
6/15/2020HC WainwrightBoost TargetBuy$1.20 ➝ $8.00High
5/21/2020AegisLower TargetBuy$15.00 ➝ $13.00High
4/13/2020AegisReiterated RatingBuy$15.00Medium
3/25/2020Cantor FitzgeraldBoost TargetOverweight$1.00 ➝ $8.00N/A
10/28/2019HC WainwrightInitiated CoverageBuy$1.20High
9/6/2019Cantor FitzgeraldInitiated CoverageOverweight$1.00High
8/8/2019AegisReiterated RatingBuy$2.90High
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Ekso Bionics logo
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $1.28
Low: $1.18
High: $1.28

50 Day Range

MA: $1.53
Low: $1.16
High: $2.10

52 Week Range

Now: $1.28
Low: $0.62
High: $3.13

Volume

105,061 shs

Average Volume

187,312 shs

Market Capitalization

$22.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Ekso Bionics?

The following Wall Street sell-side analysts have issued reports on Ekso Bionics in the last twelve months: 500.com Limited, HC Wainwright, and StockNews.com.
View the latest analyst ratings for EKSO.

What is the current price target for Ekso Bionics?

1 Wall Street analysts have set twelve-month price targets for Ekso Bionics in the last year. Their average twelve-month price target is $9.25, suggesting a possible upside of 634.1%. HC Wainwright has the highest price target set, predicting EKSO will reach $9.25 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $9.25 for Ekso Bionics in the next year.
View the latest price targets for EKSO.

What is the current consensus analyst rating for Ekso Bionics?

Ekso Bionics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EKSO will outperform the market and that investors should add to their positions of Ekso Bionics.
View the latest ratings for EKSO.

What other companies compete with Ekso Bionics?

How do I contact Ekso Bionics' investor relations team?

Ekso Bionics' physical mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company's listed phone number is (510) 984-1761 and its investor relations email address is [email protected]. The official website for Ekso Bionics is www.eksobionics.com. Learn More about contacing Ekso Bionics investor relations.